Hims & Hers Health (HIMS) Set to Announce Quarterly Earnings on Monday

Hims & Hers Health (NYSE:HIMS) will post its quarterly earnings results after the market closes on Monday, May 6th. Analysts expect Hims & Hers Health to post earnings of $0.02 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The business had revenue of $246.60 million for the quarter, compared to analyst estimates of $245.84 million. During the same period in the previous year, the company posted ($0.05) EPS. The company’s revenue was up 47.4% compared to the same quarter last year. On average, analysts expect Hims & Hers Health to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $11.26 on Friday. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of -102.36 and a beta of 0.97. The business has a 50-day moving average of $14.01 and a 200-day moving average of $10.25. Hims & Hers Health has a 1-year low of $5.65 and a 1-year high of $17.16.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of recent research reports. Piper Sandler raised their target price on shares of Hims & Hers Health from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Tuesday, February 27th. Jefferies Financial Group reissued a “hold” rating and issued a $15.00 price target (down previously from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. Citigroup upped their target price on Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. TheStreet upgraded shares of Hims & Hers Health from a “d” rating to a “c” rating in a research note on Monday, March 4th. Finally, Seaport Res Ptn reaffirmed a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Hims & Hers Health has an average rating of “Moderate Buy” and a consensus price target of $14.85.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 97,208 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total value of $931,252.64. Following the sale, the chief executive officer now owns 51,653 shares in the company, valued at $494,835.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Andrew Dudum sold 97,208 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total value of $931,252.64. Following the completion of the transaction, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at approximately $494,835.74. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 31,363 shares of Hims & Hers Health stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $10.03, for a total value of $314,570.89. Following the completion of the sale, the chief financial officer now owns 156,721 shares of the company’s stock, valued at $1,571,911.63. The disclosure for this sale can be found here. Insiders sold 736,191 shares of company stock valued at $9,733,700 in the last three months. Corporate insiders own 31.63% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.